NCT03163173View on ClinicalTrials.gov

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

October 13, 2017

Study Completion Date

October 13, 2017

Conditions
Healthy VolunteersHealthy
Interventions
DRUG

GC4419

30 mg (\~100 μCi) dose of \[14C\]GC4419

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Galera Therapeutics, Inc.

INDUSTRY